ABSTRACT The emerging application of pharmacogenomics in the clinical trial setting requires careful comparison with more traditional phenotyping methodologies, particularly in the drug metabolism area where phenotyping is used extensively. The research objectives of this study were 1) to assess the utility of cytochrome P450 2D6 (CYP2D6) genotyping as an alternative to traditional phenotyping as a predictor of poor metabolizer status; 2) to identify issues for consideration when implementing CYP2D6 genotyping in clinical trials; and 3) to outline the advantages and disadvantages of CYP2D6 genotyping compared with phenotyping. DNA samples obtained from 558 previously phenotyped individuals were blindly genotyped at theCYP2D6 locus, and the genotype-phenotype correlation was then determined. The CYP2D6genotyping methodology successfully predicted all but 1 of the 46 poor metabolizer subjects, and it was determined that this 1 individual had a novel (presumably inactive) mutation within the coding region. In addition, we identified 2 subjects with CYP2D6 genotypes indicative of poor metabolizers who had extensive metabolizer phenotypes as determined by dextromethorphan/dextrorphan ratios. This finding suggests that traditional phenotyping methods do not always offer 100% specificity. Our results suggest that CYP2D6 genotyping is a valid alternative to traditional phenotyping in a clinical trial setting, and in some cases may be better. We also discuss some of the issues and considerations related to the use of genotyping in clinical trials and medical practice.
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Introduction
Cytochrome P450s comprise the major enzymes involved with Phase I metabolism of xenobiotics. One of these enzymes, cytochrome P450 2D6 (CYP2D6), processes about 20% of all commonly prescribed drugs, and many compounds currently in clinical development are known to be CYP2D6 substrates. This enzyme has a wide range of activity within human populations, with interindividual rates of metabolism differing more than 10 000-fold (1) (2) (3) (4) . This variation poses a challenge to drug development as it results in difficulty in predicting dosing, safety, and efficacy. Most individuals are able to metabolize CYP2D6 substrates extensively(extensive metabolizers [EMs] ), whereas 7% to 10% of Caucasian individuals produce no functional CYP2D6 enzyme and are forced to use an alternative metabolic pathway (poor metabolizers [PMs] ultrarapid metabolization may be a result of multiple tandem copies of the CYP2D6 gene in one individual. Because of such large potential differences in pharmacokinetics, clinicians are at an advantage if they know the metabolic status of the subjects enrolled in clinical studies for drugs known to be metabolized by CYP2D6, and often attempts are made to determine a subject's metabolic status before administration of a drug in clinical trials. Better decisions regarding drug dosing, safety, and efficacy can be made with knowledge of the subject's CYP2D6 status.
CYP2D6 metabolic status has traditionally been determined by administering a probe drug that is known to be a CYP2D6-specific substrate, such as dextromethorphan or debrisoquine. Urine samples are then collected at a certain time point, and the ratio of unchanged drug to metabolite is determined by high-performance liquid chromatography or gas chromatography (5, 6) . Although this phenotyping methodology is reliable, some problems are associated with it. Intraindividual variability may be significant, and the length of time it takes to determine metabolic status delays administration of the test drug. Careful drug screens must be used because there may be significant drug-drug interactions with CYP2D6 inhibitors or inducers that can lead to inaccurate metabolic measurements (7, 8) . Finally, the rate of metabolism of the probe drug may not be a reflection of that of the test drug.
Several studies have shown that much of the interindividual variation found in CYP2D6 metabolic activity is a result of genetic polymorphisms within the CYP2D6 gene (1, 4, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Alleles that result in increased, decreased, or no enzyme activity have been identified, characterized (9, 10, 12, 19, 20) , and used to support studies investigating the use of genotyping to predict the metabolic status of an individual (3, (21) (22) (23) (24) . Genotyping could have major advantages over phenotyping in that intraindividual variability is not an issue and results can be obtained more quickly. Current genotyping methodologies are simple polymerase chain reaction (PCR)-based assays that require only a small amount of whole blood from a patient, and the techniques used are easily adaptable in any molecular biology laboratory.
With the emerging interest in the field of pharmacogenomics, we feel that CYP2D6genotype-phenotype correlation could serve as an early validation of the increasingly important role that human genetics will play in the clinical development and marketing of therapeutics (15) . We assessed the utility of CYP2D6 genotyping as an alternative or replacement to the traditional.6 phenotyping methods by genotyping 558 patients who had previously been metabolically characterized through phenotyping.
Materials and Methods
Genomic DNA was isolated from whole blood from each of the 558 subjects, and the CYP2D6 genotype was determined using a modified version of the methodology described by Sachse et al (3) (see Appendix 1) . The methodology uses several PCR assays to screen for single nucleotide polymorphisms within the CYP2D6 gene as well as gene duplication and deletion (25) and pseudogene hybrid formation (19) . Results from the individual assays were used to determine the ultimate CYP2D6 genotype. Table 1 shows the mutations that were screened for and their presence in each of the established CYP2D6 alleles, of which at least 18 are known. To determine the CYP2D6 genotype, data from each of the assays were examined collectively and compared with Table 1 . Some of the alleles share several point mutations, and therefore each individual mutation detected was accounted for. It was important to distinguish between heterozygotes and homozygotes, as homozygotes have two identical mutations, one on each chromosome strand, whereas heterozygotes have the mutation on only one strand. For example, the alleles *2, *10, and *4 share the point mutations G4268C and G1749C, and *10 and *4 share C188T. Thus, a patient sample that had detected mutations of G1934A, C188T, C4268C, C2938T, and C1749C would have a genotype of *2/*4, while a patient sample that had detected mutations of C188T, C4268C, C2938T, and C1749C would have a genotype of *2/*10. The ultimate CYP2D6 genotype, which is the combination of the two alleles (one on each chromosome) detected in the sample, can be represented by a classification system that considers the number of functional alleles in the genotype when making phenotypic predictions (3). One could possess 0, 1, 2, or 3+ functional alleles depending on the genotype, as in Figure 1 . In this classification system, functional alleles include *1, *2, *9, *10, and *17. Nonfunctional alleles include *3, *4, *5, *6, *7, *8, *11, *12, *13, *14, *15, *16, and *4XN. Individuals with a *1xN or *2xN could be considered to possess additional functional alleles dependent on the number of tandem copies of the gene.
The PM, EM, UM, and IM groups are not well defined for either phenotype or genotype. Typically, the arbitrarily placed cutoff between EM and PM is 0.3 for the plasma ratio of dextromethorphan substrate to the dextrorphan metabolite and 12.6 for the debrisoquine/4-hydroxydebrisoquine plasma ratio (26) . There is, however, no arbitrarily defined cutoff for UM/EM, EM/IM, and IM/PM phenotype borders. Thus, we have loosely termed phenotypes in the range of <0.001 to 0.08 as EM, 0.08 to 0.3 as IM, and >0.3 as PM for dextromethorphan/dextrorphan; and <0.05 to 6 as EM, 6 to 12.6 as IM, and >12.6 as PM for debrisoquine/4-hydroxydebrisoquine. We chose not to include UM as a category at this time. In most cases, an EM or PM distinction would probably suffice, but we were also interested in investigating the utility of the IM category..8
Results and Discussion
Each of the 558 subjects whom we genotyped had been previously phenotyped using either dextromethorphan or debrisoquine, thereby allowing us to investigate genotype/phenotype correlation and ability to predict metabolic status from genotype. All but 2 of the subjects who had a CYP2D6 genotype containing no functional alleles had a PM phenotype. These 2 exceptions were confirmed by DNA sequencing to have *4/*4 and *3/*4 genotypes, which are indicative of PMs, yet the DM/DX ratios were 0.062 and 0.1078, respectively. This suggests an inaccurate measure of phenotype because no functional CYP2D6 enzyme would be present in these individuals. Each of the patients with one or more functional alleles, with 1 exception, had an EM or IM phenotype. This 1 exception had a calculated genotype of *2/*3 (1 functional allele) and a PM phenotype of metabolic ratio equal to 1.962. Each of the CYP2D6 exons and exon-intron boundaries from this patient were sequenced, and a novel polymorphism was detected. Because this polymorphism results from a nucleotide insertion in exon 9, we suspect that it contributed to the PM status of the patient (manuscript in preparation). Table 2 shows the polymorphisms that were interrogated and whether they were detected in any of the 558 patients analyzed. Several of the PM alleles (*7, *8, *11, *12, and *14) were not detected in any of the 558 samples (1116 chromosomes). Table 3A outlines the genotype distribution among PM subjects, and Table 3B details the allelic contribution to PM genotypes. The PM alleles *3, *4, and *5 accounted for more than 95% of the contribution to PM genotypes, but the extended screen that included the less common PM alleles (those with a frequency of less than 0.001) was able to detect an additional 4 PM subjects who would have been missed if we had performed genotyping for only the most common alleles. The extended screen did not, however, detect the novel polymorphism in exon 9 of one subject, which presumably contributed to that subject's PM status. Finally, one of the PM alleles, *16, was not found in any of the PMs, yet it was detected in 1 EM subject with a genotype of *1/*16. It is important to note that a rare PM allele, when present, may not necessarily contribute to a PM phenotype as long as it is paired with a functional allele, as PM status is a recessive condition.
The ability of molecular genetics to correlate with drug exposure is an early validation of the emerging field of pharmacogenomics. In this study and others (3, 23) , CYP2D6 genotyping has proven to be a valid alternative to traditional phenotyping for determination of poor metabolizer status. Given the correlation between CYP2D6 genotype and phenotype, we believe that CYP2D6 genotyping should be used in the clinical trial setting. In our study we identified two individual phenotypic measurements that were predictive of subjects who would have exhibited an extensive metabolizer status yet were genotyped as poor metabolizers, which was then confirmed by DNA sequencing of genomic DNA from the subjects. Therefore, in the context of these clinical development studies, traditional phenotyping did notoffer 100% specificity. This discrepancy could have resulted from sample handling or data reporting errors or assay failure. We were unable to go back to the individual subjects to reanalyze the phenotype.
Genotyping methodologies can be easier to use than biochemical measurements in a clinical setting. Genotyping requires only a single sample, whereas biochemical measurements often require various body fluids and/or tissue biopsies taken at multiple time points. Often a very small amount of material, such as blood from a single finger prick or a buccal swab, is all that is needed to complete genotyping assays. Genotyping results can often be obtained more quickly than phenotyping results, and future technologies may offer rapid "bedside" assessment. For assessment of CYP2D6 status, samples for genotyping can be obtained at the screening visit, and results can be obtained before the wash-out period is over; phenotyping usually cannot be performed until after the wash-out period. Because an individual's DNA sequence does not change over time, genotyping for a particular gene needs only to be performed once, whereas biochemical measurements may need to be taken numerous times. Finally, genotyping is likely to be less expensive, especially as new high-throughput technologies become available.
CYP2D6 genotyping methodology is well documented and should be easy for any molecular biology laboratory to adapt. Genotyping should yield the same results across different laboratories, thus making it ideally suited to a diagnostic application (30) ; in contrast, phenotyping may yield more variable data between laboratories and at different time points for the same patient. Intraindividual variation does not exist in genotype data; on any given day a patient's genotype will be exactly the same. This constancy does not apply to CYP2D6 phenotypes because other factors, such as certain foods, tobacco usage, and drug-drug interactions, can act as CYP2D6 inducers or inhibitors and thus give an incorrect measure of CYP2D6 metabolic rate upon administration of the probe drug. This fact could be particularly important in clinical trials of neurotrauma drugs in which the patient may be unconscious. The nature of these compounds and their ability to penetrate the blood-brain barrier make them susceptible to CYP2D6 metabolism, and if the patient is unconscious, a physician may have no knowledge of drugs that the patient may have been taking that are CYP2D6 inducers or inhibitors (Table 4) . Even though in such cases genotyping would give an accurate prediction of metabolic status (while phenotyping might not), a physician still needs to be aware of other factors that can introduce variability in CYP2D6 metabolism.
CYP2D6 genotyping is also a flexible methodology in that one can decide which alleles to interrogate depending on the needs of each particular study. The advantage of screening for all known alleles is to increase our ability to safely test new therapeutic entities. However, screening for the most common PM alleles (*3, *4, *5) will typically identify about 95% of the PMs in a sample set. There are, however, several other PM alleles that result in a complete loss of enzyme activity, some of which are extremely rare. For example, *13, which was not included in this study because we had no positive control group, may have an allele frequency as low as 0.0001 (19) . Not including a screen for rare alleles may result in a missed PM. In addition, screening for alleles that result in a decreased enzyme function (particularly *10), as opposed to no enzyme function, may be beneficial. For example, Asian populations are known to have a higher allelic frequency of the *10 allele (27-29), which could help explain the overall lower capacity of Asian patients to metabolize CYP2D6 substrates. Although the genotypic prediction of IM status was correlated with an IM phenotype only 10% of the time in our study, the use of the IM category can be quite useful in Phase I trials in which the safety and efficacy windows are unknown. In addition, some alleles share several polymorphisms, thereby offering a quality check on the determined genotype. For example, the *4 allele has not only G1934A, but also shares C188T, G4268C, and G1749C with *10. Thus, if G1934A is the only mutation detected, one might hesitate to claim that the genotype contains a *4 allele. One strategy for increasing genotyping efficiency might be to develop a protocol that includes an initial screen for the more common PM alleles (*3, *4, *5, *6, and *16) and, in cases where none of these alleles are detected, a screen for the less common PM alleles and IM alleles.
CYP2D6 genotyping may be helpful in drug-drug interaction studies of novel therapeutics. In such studies where there is interpatient variability in safety or efficacy, one might conclude that there is some kind of relevant interaction between the two administered drugs and that this interaction is responsible for the observed variability. However, examination of the CYP2D6 genotype (and/or those of other drug-metabolizing enzymes) may reveal that the variability was attributable to poor metabolizer status in those patients in whom variability was observed. We have used CYP2D6 genotyping in several drug-drug interaction studies in which a test drug was co-administered with dextromethorphan or paroxetine, two drugs known to be metabolized by CYP2D6, and concluded that the interpatient variability observed was indeed attributable to poor metabolizer status.
Prospective CYP2D6 genotyping for enrollment purposes may be extremely useful in Phase I first-inhuman (FIH) studies where safety and efficacy profiles are essentially unknown. For safety purposes, a clinician may initially choose to enroll only subjects with 2 active alleles. Genotype can be compared with data on pharmacokinetic variability, adverse events, and drug response to aid in the decision-making process for subsequent studies for the compound, eventually including PM individuals. This information is important for all drugs in development, no matter which metabolizing enzymes are involved, as it could help make clinical trials safer with respect to drug metabolism. In clinical trials in which significant variability in drug response or pharmacokinetic data are observed, retrospective genotyping is probably easier to use and more informative than retrospective phenotyping. A further benefit of genotyping is that the comparison of genotype and pharmacokinetic data is likely to indicate an individual's rate of metabolism for a particular drug, whereas the rates of metabolism of probe drug and test drug may be significantly different in a phenotype screen.
CYP2D6 genotyping is likely to assist clinicians in finding drug doses that are safe and efficacious for both EMs and PMs, or perhaps in tailoring drug dosage to an individual's needs, with EMs and PMs receiving differential dosing.
Although genotyping has many advantages over phenotyping in a clinical trial setting, it also has some limitations. First, the described PCR-RFLP methodology has some technical shortcomings. For example, some of the assays are prone to false negatives because they rely on the presence or absence of a PCR product. In addition, the RFLP banding patterns and band intensities may be confusing (see Appendix 2) . Using this methodology, one could potentially miss some PMs because a rare polymorphism or a novel functional polymorphism was not screened for. This illustrates one major limitation of CYP2D6 genotyping by the methodology described. By screening only for known CYP2D6 polymorphisms, PMs with novel or rare polymorphisms that result in no enzyme activity could be missed. However, in screening 1116 chromosomes we identified only one novel allele that contributed to a PM phenotype; therefore, the PCR-RFLP methodology should be reliable more than 99.5% of the time. Second, even though genotype is an excellent predictor of CYP2D6 poor metabolizer status, it is probably not an absolute predictor of catalytic function (22) . Patients of a single common genotype have DX/DM ratios over a 1000-to 10 000-fold range, yet there is a significant gene-dose effect for both debrisoquine and dextromethorphan for all PM-IM-EM-UM differences (Figure 1 ). The precise reason for this range is unknown but is probably due to diet, differential expression of the CYP2D6 gene, inherent backup metabolism systems, significant interlaboratory and intraindividual variability in phenotype data, and possible combinations of other minor undetected genetic polymorphisms in the CYP2D6 gene (28) . CYP2D6 genotyping could, therefore, be challenging for therapies with narrow therapeutic indices, as intermediate metabolizers cannot be readily identified. Third, specific drug-drug interactions can convert extensive metabolizers to poor metabolizers. While this is a minor issue in the clinical trial setting where concombinant medicines can be carefully screened, drug-drug interactions in a traditional medical care setting can have extremely important consequences because patients can be far more difficult to monitor. CYP2D6genotyping would be of little use in such cases where it is a drug-drug interaction, not metabolic status, that is problematic. A final limitation of genotyping is the ethical issue surrounding anonymous and non-anonymous genotyping. Patients may feel that genetic studies are an invasion of their privacy, and some may worry that employers or insurance companies could get access to genotype data. However, genotyping of the drug-metabolism genes may present fewer ethical issues because, generally, these genes have not been associated with increased risk for disease. Still, for legal and ethical reasons, genotyping in clinical trials requires new consent forms and institutional review board approval.
While genotyping may become an integral part of clinical development, its future in medical practice is less certain. The field of pharmacogenomics will provide an explosion of genetic data that could potentially have an enormous impact on drug development from discovery research through postmarketing.
Discovery research in pharmacogenomics can enhance our ability to establish the therapeutic relevance of novel candidate genes in humans through genetic association studies that reveal novel associations with particular human phenotypes. In early clinical development, the assessment of polymorphic drug-metabolizing enzyme genotypes in all Phase I studies will aid in a comprehensive understanding of pharmacokinetic variability. Additionally, the investigation of therapeutic target variation early in development will better define patient subpopulations and potentially enhance our understanding of efficacy and safety. In Phase III studies, large patient populations will allow the possible identification of those subpopulations where efficacy and safety issues are imperative for drug approval. Similarly, issues arising postmarketing could be addressed with postmarketing collection of DNA samples and subsequent pharmacogenomic analyses.
How the pharmaceutical industry will use this wealth of information is uncertain. Private companies and regulatory agencies alike will have to determine the value of pharmacogenomics in the marketplace as opposed to in the clinical trial setting. From a drug metabolism standpoint, genetic data may never be as informative as drug level monitoring, but if the purpose is simply to prevent poor metabolizers from pursuing a particular therapy due to safety issues, a simple diagnostic genotyping assay may be required for prescriptions to be written. Although a push for diagnostic genotyping would likely complicate drug development issues, we should strive to maintain the same high standards in the marketplace that we do in the clinical trial setting. The choice of whether to use genotyping in diagnostic assays will probably initially be made on a case-by-case basis and will be driven by the sensitivity and specificity of the genetic diagnostic, the cost/benefit of such a diagnostic, and the perceived need.
Conclusions
In conclusion, CYP2D6 genotyping is a valid alternative to traditional phenotyping, and in many cases genotyping is uniquely well suited to the clinical trial setting. Pharmacogenomics is a rapidly evolving area with many technological advances that will increase throughput and decrease costs for genotyping assays. In many respects the CYP2D6 gene represents a challenge for genotyping because the numerous polymorphisms are not only single nucleotide in nature, but are also gene deletion, duplication, and pseudogene derivatives. Yet this genetic information promises to optimize drug therapy by potentially decreasing the number of adverse events through individualized dosing dependent on a patient's CYP2D6 genotype. Future technologies that might be used for CYP2D6 genotyping in the patient setting include TaqMan allelic discrimination (eg, PerkinElmer-Applied Biosystems, Wellesley, MA) DNA chip-based assays for specific alleles (eg, Affymetrix, Santa Clara, CA), or MALDI-TOF mass spectrometric methods (eg, Sequenom, San Diego, CA). All of these technologies, however, have the limitation that they can only detect known single nucleotide polymorphisms. Given the large amount of genetic diversity at the CYP2D6 locus, it is likely that there are more novel mutations that result in a loss of enzyme activity. Ideally, the emerging genotyping technologies will be able to detect these rare mutations so that no poor metabolizers would be missed. The ideal CYP2D6genotyping technology would be a high-throughput sequencing platform that allows an individual's entire CYP2D6 gene to be rapidly sequenced. The establishment of pharmacogenomic service laboratories associated with CROs will greatly facilitate the incorporation of genotyping in clinical trials. One can imagine a day when the use of genotyping to determine CYP2D6 metabolic status, as well as the status of other important polymorphic drug-metabolizing enzymes, may be an integral part of patient care and therapeutic management.
Appendix 1. CYP2D6 Genotyping Methodology

Subjects and Methods
Subjects
All the studies in which whole blood was obtained were approved by the appropriate institutional human experimentation committees in accordance with all applicable regulations. Three hundred thirtysix unrelated Caucasian German individuals described previously (3) and 222 patients from various Pfizer clinical trials (primarily unrelated Caucasian males) were studied for CYP450 2D6 metabolic status with appropriate informed consent.
Phenotyping Methods
Each of the 558 subjects was phenotyped for their CYP450 2D6 metabolic status. Of the German individuals, 302 were phenotyped with dextromethorphan and 34 with debrisoquine, as described (3) . Each of the Pfizer subjects was phenotyped with dextromethorphan (6).
Genotyping Methods.
Genomic DNA was isolated from whole blood from each of the 558 subjects using either the QIAmp Blood Kit (QIAGEN, Valencia, CA) (Pfizer samples) or the method of Sambrook et al (31) (German samples). The 336 German samples were first genotyped in Berlin as described (3) and then genotyped using a modified methodology described below at Pfizer in Groton, CT, for a crosslaboratory comparison of CYP450 2D6 genotyping methodology. The 222 Pfizer samples were also genotyped using this modified methodology.
Minor modifications were made to the established methodology of Sachse et al (3) . All PCR reactions were performed in PerkinElmer MicroAmp Optical plates (96 well) using either Perkin Elmer GeneAmp PCR System 9600 or 9700 thermocyclers. All PCR reagents were from PerkinElmer. Restriction enzymes were from New England BioLabs (Beverly, MA), except for MaeII, which was from Boehringer Mannheim. SeaKem GTG and MetaPhor agarose for gel electrophoresis were both from FMC BioProducts (now a subsidiary of Cambrex, East Rutherford, NJ). Table  5 outlines the CYP2D6 genotyping methodology used at Pfizer.
Results from the individual assays were used to determine the ultimate CYP2D6 genotype. Table 1 shows the mutations that were screened for and their presence in each of the established CYP2D6 alleles. To determine the CYP2D6 genotype, data from each of the assays were examined collectively and compared with Table 1 . It was important to distinguish between heterozygotes and homozygotes, as homozygotes have two identical mutations, one on each chromosome strand, whereas heterozygotes have the mutation on only one strand. Some of the alleles share several point mutations, and therefore each individual mutation detected was accounted for. For example, the alleles *2, *10, and *4 share the point mutations G4268C and G1749C, and *10 and *4 share C188T. Thus, a patient sample that had detected mutations of G1934A, C188T, C4268C, C2938T, and C1749C would have a genotype of *2/*4, while a patient sample that had detected mutations of C188T, C4268C, C2938T, and C1749C would have a genotype of *2/*10.
Sequencing of Exons and Intron-Exon Boundaries
Initial amplification product was used as a template for nested PCR amplifications in which the products spanned exons and intron-exon junctions. Nested primers were tagged with M13 universal primers for ease of direct cycle sequencing. Primer sequences are shown in Table 6 . Each 100 μL reaction contained 1X PCR Buffer II, 2.5 mmol/L MgC l 2, 0.2 mmol/L dNTPs, 0.2 μmol/L primers, 2.5 units of AmpliTaq Gold, and diluted initial amplification product. Cycling parameters on the 9600 were
